Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Enterprise Value: 2021-2025

Historic Enterprise Value for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $2.3 billion.

  • Kiniksa Pharmaceuticals International's Enterprise Value rose 64.19% to $2.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 117.09%. This contributed to the annual value of $1.2 billion for FY2024, which is 15.30% up from last year.
  • Kiniksa Pharmaceuticals International's Enterprise Value amounted to $2.3 billion in Q3 2025, which was up 47.17% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Enterprise Value ranged from a high of $2.3 billion in Q3 2025 and a low of $459.1 million during Q1 2022.
  • Its 3-year average for Enterprise Value is $1.2 billion, with a median of $1.1 billion in 2024.
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 46.29% in 2022, then soared by 69.44% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Enterprise Value (MRQ) stood at $628.6 million in 2021, then surged by 35.37% to $851.0 million in 2022, then grew by 20.73% to $1.0 billion in 2023, then grew by 15.30% to $1.2 billion in 2024, then soared by 98.25% to $2.3 billion in 2025.
  • Its Enterprise Value was $2.3 billion in Q3 2025, compared to $1.6 billion in Q2 2025 and $1.2 billion in Q1 2025.